Hearn Bevin, Delbello David, Lawler Joseph, Ng Michel, Harty Alyson, Dieterich Douglas T
Dr Hearn and Dr Delbello are fellows in the Division of Infectious Diseases; Dr Lawler is a fellow in the Division of Liver Diseases; Mr Ng is a nurse practitioner in the Division of Infectious Diseases and the Division of Liver Diseases; Ms Harty is a nurse in the Division of Liver Diseases; and Dr Dieterich is a professor in the Division of Infectious Diseases and the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, New York.
Gastroenterol Hepatol (N Y). 2014 Nov;10(11):706-715.
Between 15% and 30% of patients infected with HIV in the United States and Europe are coinfected with hepatitis C virus (HCV), and rates of acute HCV infection have been increasing in some populations of HIV-positive patients. Liver disease is now a leading cause of death in HIV-infected patients. Patients with HIV/HCV coinfection have lower rates of spontaneous acute HCV clearance, poorer response to treatment of chronic HCV in the pre-direct-acting antiviral era, more rapid progression to cirrhosis, and increased risk of hepatocellular carcinoma. This article will summarize data on management of HIV/HCV coinfection, discuss the epidemic of acute HCV infection in HIV-infected patients, and examine the many new HCV treatment regimens on the horizon with data on coinfected patients.
在美国和欧洲，15%至30%的艾滋病毒感染者同时感染了丙型肝炎病毒（HCV），并且在一些艾滋病毒阳性患者群体中，急性HCV感染率一直在上升。肝病现已成为艾滋病毒感染者的主要死因。艾滋病毒/HCV合并感染的患者自发急性HCV清除率较低，在前直接抗病毒药物时代对慢性HCV治疗的反应较差，肝硬化进展更快，肝细胞癌风险增加。本文将总结艾滋病毒/HCV合并感染的管理数据，讨论艾滋病毒感染者中急性HCV感染的流行情况，并结合合并感染患者的数据研究即将出现的许多新的HCV治疗方案。
